The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

Sven Tyge Langkjer, Julia Kenholm, Jeanette Dupont Jensen, Kim Wedervang, Annette Torbøl Brixen, Mie Grunnet, Lars Stenbygaard, Bjørnar Gilje, Hella Danø, Vesna Glavicic, Erik Hugger Jacobsen, Anne Sofie Brems-Eskildsen, Helle Lemvig Kruse, Trine Dongsgaard, Jeppe Neimann, Jürgen Geisler

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

OriginalsprogEngelsk
TidsskriftFuture Oncology
Antal sider9
ISSN1479-6694
DOI
StatusE-pub ahead of print - 19 jun. 2019

Fingerprint

Breast Neoplasms
Lung Neoplasms
Drug Therapy
Maximum Tolerated Dose
Antineoplastic Agents
vinorelbine
Quality of Life
Clinical Trials
Survival
Therapeutics

Citer dette

Langkjer, S. T., Kenholm, J., Jensen, J. D., Wedervang, K., Brixen, A. T., Grunnet, M., ... Geisler, J. (2019). The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer. Future Oncology. https://doi.org/10.2217/fon-2019-0124
Langkjer, Sven Tyge ; Kenholm, Julia ; Jensen, Jeanette Dupont ; Wedervang, Kim ; Brixen, Annette Torbøl ; Grunnet, Mie ; Stenbygaard, Lars ; Gilje, Bjørnar ; Danø, Hella ; Glavicic, Vesna ; Jacobsen, Erik Hugger ; Brems-Eskildsen, Anne Sofie ; Kruse, Helle Lemvig ; Dongsgaard, Trine ; Neimann, Jeppe ; Geisler, Jürgen. / The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer. I: Future Oncology. 2019.
@article{5123a1876c524339aaec62ed5fadc481,
title = "The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer",
abstract = "Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.",
author = "Langkjer, {Sven Tyge} and Julia Kenholm and Jensen, {Jeanette Dupont} and Kim Wedervang and Brixen, {Annette Torb{\o}l} and Mie Grunnet and Lars Stenbygaard and Bj{\o}rnar Gilje and Hella Dan{\o} and Vesna Glavicic and Jacobsen, {Erik Hugger} and Brems-Eskildsen, {Anne Sofie} and Kruse, {Helle Lemvig} and Trine Dongsgaard and Jeppe Neimann and J{\"u}rgen Geisler",
year = "2019",
month = "6",
day = "19",
doi = "10.2217/fon-2019-0124",
language = "English",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

Langkjer, ST, Kenholm, J, Jensen, JD, Wedervang, K, Brixen, AT, Grunnet, M, Stenbygaard, L, Gilje, B, Danø, H, Glavicic, V, Jacobsen, EH, Brems-Eskildsen, AS, Kruse, HL, Dongsgaard, T, Neimann, J & Geisler, J 2019, 'The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer' Future Oncology. https://doi.org/10.2217/fon-2019-0124

The NAME trial : a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer. / Langkjer, Sven Tyge; Kenholm, Julia; Jensen, Jeanette Dupont; Wedervang, Kim; Brixen, Annette Torbøl; Grunnet, Mie; Stenbygaard, Lars; Gilje, Bjørnar; Danø, Hella; Glavicic, Vesna; Jacobsen, Erik Hugger; Brems-Eskildsen, Anne Sofie; Kruse, Helle Lemvig; Dongsgaard, Trine; Neimann, Jeppe; Geisler, Jürgen.

I: Future Oncology, 19.06.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - The NAME trial

T2 - a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer

AU - Langkjer, Sven Tyge

AU - Kenholm, Julia

AU - Jensen, Jeanette Dupont

AU - Wedervang, Kim

AU - Brixen, Annette Torbøl

AU - Grunnet, Mie

AU - Stenbygaard, Lars

AU - Gilje, Bjørnar

AU - Danø, Hella

AU - Glavicic, Vesna

AU - Jacobsen, Erik Hugger

AU - Brems-Eskildsen, Anne Sofie

AU - Kruse, Helle Lemvig

AU - Dongsgaard, Trine

AU - Neimann, Jeppe

AU - Geisler, Jürgen

PY - 2019/6/19

Y1 - 2019/6/19

N2 - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

AB - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.

U2 - 10.2217/fon-2019-0124

DO - 10.2217/fon-2019-0124

M3 - Journal article

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -